Home › Graves Ophthalmopathy › NCT03708627
Bimatoprost as a Treatment for Graves' Orbitopathy
RecruitingEarly phase 1
The Role of Bimatoprost in Graves' Periorbitopathy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis - Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids \-
About the study
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
What is being tested
- Bimatoprost Ophthalmic (drug)
Sponsor: Johns Hopkins University · Participants: 3 · Started: Nov 1, 2017
Contact the study team
- Emily Li, MD · Phone: 410-955-1112
Official record on ClinicalTrials.gov — NCT03708627
Locations in the U.S.
| Washington | University of Washington, Seattle |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.